Germany's Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion

Impact · against what's priced in

Silence Therapeutics is expected to gap up toward $20 following a cash acquisition offer by Merck at a premium of over 100%. The transaction is a neutral event for Merck's valuation.

SLCE+1.00

No priced-in read yet

In context

The offer of $20 per share represents more than double the closing price from Friday, providing a direct and immediate catalyst for a price increase.

Read from the article alone

Actual

• biotech▲19%
• m and a
• SLCE
• acquisition
• cash offer
• pharma

Top 1 mover · tap to explore